City of Hope Initiates Clinical Trial for Wearable Biosensor Patch to Non-Invasively Monitor Oxygen, CO, Glucose, and Inflammatory Markers Perioperatively

July 12, 2026

ClinicalTrials.gov (via Power.com) USA

Overview

City of Hope Medical Center has launched a clinical trial (NCT07612085) to evaluate the feasibility and safety of a wearable biosensor patch for non-invasive, real-time monitoring of oxygen, carbon monoxide, glucose, and inflammatory markers in patients undergoing abdominal or thoracic surgery. This patch has the potential to significantly enhance patient recovery and care quality by providing real-time data, enabling early detection of postoperative complications, and facilitating rapid adjustments to treatment plans.

In Depth

Key Findings

City of Hope Medical Center has initiated a clinical trial (NCT07612085) to assess the feasibility and safety of an innovative wearable biosensor patch designed for non-invasive, real-time monitoring of critical physiological biomarkers during and after abdominal or thoracic surgery. This patch could represent a significant advancement in optimizing patient recovery and reducing the risk of postoperative complications, ultimately enhancing the quality of perioperative care.

Technical and Clinical Details

Target Biomarkers: The wearable patch is engineered to concurrently monitor multiple vital physiological indicators, including oxygen saturation, carbon monoxide levels, glucose concentration, and inflammatory markers. These biomarkers are crucial for assessing patient stability and detecting potential complications during the postoperative recovery period.
Non-Invasive, Real-Time Monitoring: The patch is applied to the skin, collecting data non-invasively. This approach aims to reduce patient discomfort and infection risks associated with traditional invasive monitoring methods. The provision of real-time data empowers healthcare professionals to promptly recognize changes in patient status and make rapid clinical decisions.
Clinical Trial Objectives: The primary objectives of this trial are to evaluate the feasibility (e.g., reliability of data collection, ease of application) and safety (e.g., incidence of skin irritation, discomfort, device-related complications) of this wearable biosensor patch in a surgical patient population. While specific patient numbers or detailed trial duration results are not yet available, it is understood to be a Phase 1 feasibility and safety study.
Improved Postoperative Care: The postoperative recovery phase carries a high risk of complications such as infections, hemorrhage, and metabolic disturbances. Continuous monitoring with this patch could enable early detection of these issues, potentially improving patient outcomes through timely interventions.

Background and Industry Context

Postoperative patient monitoring is paramount for patient safety and recovery, but current standard methods often have limitations, including intermittent measurements, invasiveness, and increased burden on nursing staff. Advances in wearable technology offer new opportunities to address these challenges, driving remote patient monitoring (RPM) and personalized postoperative care through the provision of real-time, continuous physiological data. Investment in this area by leading medical institutions like City of Hope underscores the potential for wearable biosensors to play an indispensable role in future healthcare.

Strategic Significance and Outlook

Successful completion of this clinical trial could lead to a paradigm shift in postoperative care. Patients may benefit from continuous monitoring not only in hospital settings but also at home post-discharge, potentially leading to reduced readmission rates and improved quality of life. In the future, such wearable patches are expected to integrate with artificial intelligence (AI) systems, automating anomaly detection and issuing risk alerts, thereby streamlining healthcare workflows and extending high-quality monitoring to a larger patient population. This technology also holds promise for broader applications in critical care and chronic disease management beyond surgical contexts.

Source: https://www.withpower.com/trial/phase-hematopoietic-and-lymphatic-system-neoplasm-8-2026-a9198

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.